The Cost-Effectiveness of Biologic Dmards in Patients With Severe or Mild-To-Severe Rheumatoid Arthritis After Conventional Dmards

To estimate the cost-effectiveness of biologic disease modifying anti-rheumatic drugs (bDMARDs) following failure of conventional disease modifying anti-rheumatic drugs (cDMARDs) in patients with severe or mild-to-severe active rheumatoid arthritis from a UK, NHS perspective, as part of an ongoing National Institute of Health and Care Excellence (NICE) appraisal. Systematic review of clinical effectiveness of seven bDMARDs: abatacept;...